Links

Tools

Export citation

Search in Google Scholar

Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study

Journal article published in 2015 by L. Idolazzi, S. Adami, R. Capozza, G. Bianchi, A. Cozzolongo, O. Epis, O. Episs, E. Fusaro ORCID, G. Lapadula, A. Migliore, R. Pellerito, A. Pucino, L. Sinigaglia, Elisa Visalli ORCID, Maurizio Rossini
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload

Abstract

Methotrexate (MTX) is the first choice in the treatment of rheumatoid arthritis (RA), but the doses and regimens vary significantly. For this purpose, we conducted an observational study on the use of MTX for RA in Italy (MARI study).